Adverse Reactions to Biologics in Psoriasis

Current Problems in Dermatology (Switzerland)

Volumn 53, Issue , 2017, Pages 1-14

  Lockwood, Stephen J ^a   Prens, Lisette M ^a   Kimball, Alexa B ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; IXEKIZUMAB; METHOTREXATE; RETINOID; SECUKINUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; VITAMIN D DERIVATIVE; CYTOKINE; DERMATOLOGICAL AGENT; IL17A PROTEIN, HUMAN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ALOPECIA; APLASTIC ANEMIA; ARTHRALGIA; ARTICLE; BENCHMARKING; BIOLOGICAL THERAPY; CANDIDIASIS; CARDIOVASCULAR DISEASE; CHICKENPOX; DELAYED HYPERSENSITIVITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECZEMA; HEADACHE; HEART FAILURE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; INFECTION; INJECTION SITE REACTION; LEUKOCYTOCLASTIC VASCULITIS; LICHEN PLANUS; LIVER TOXICITY; LUPUS LIKE SYNDROME; MAJOR ADVERSE CARDIAC EVENT; MALIGNANT NEOPLASM; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; NON MELANOMA SKIN CANCER; NONHUMAN; OPTIC NEURITIS; PANCYTOPENIA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PREGNANCY; PRIORITY JOURNAL; PSEUDOLYMPHOMA; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; TUBERCULOSIS; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS;

ADALIMUMAB; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL PRODUCTS; CYTOKINES; DERMATOLOGIC AGENTS; ETANERCEPT; HUMANS; INFLIXIMAB; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA; USTEKINUMAB;

EID: 85033498305     PISSN: 14215721     EISSN: 16622944     Source Type: Book Series    
DOI: 10.1159/000478072     Document Type: Article

References (108)

1. Ludwig RJ, Herzog C, Rostock A, et al: Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-276.
2. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ: Prevalence and treatment of psoriasis in the United Kingdom: a populationbased study. Arch Dermatol 2005; 141: 1537-1541.
3. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H: Trends in incidence of adult-onset psoriasis over three decades: a populationbased study. J Am Acad Dermatol 2009; 60: 394-401.
4. Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H: Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol 2010; 62: 979-987.
5. Mervic L: Management of moderate to severe plaque psoriasis in pregnancy and lactation in the era of biologics. Acta Dermatovenerol Alp Pannonica Adriat 2014; 23: 27-31.
6. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
7. Gisondi P, Tessari G, Conti A, et al: Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
8. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM: Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
9. Wu JJ, Nguyen TU, Poon KY, Herrinton LJ: The association of psoriasis with autoimmune diseases. J Am Acad Dermatol 2012; 67: 924-930.
10. Wakkee M, de Vries E, van den Haak P, Nijsten T: Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a populationbased cohort. J Am Acad Dermatol 2011; 65: 1135-1144.
11. Rapp SR, Feldman SR, Exum ML, Fleischer AB et al., Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
12. Vanderpuye-Orgle J, Zhao Y, Lu J, et al: Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol 2015; 72: 961-967.e5.
13. Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009; 361: 496-509.
14. Menter A, Feldman SR, Weinstein GD, et al: A randomized comparison of continuous vs. Intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1-e15.
15. Menter A, Tyring SK, Gordon K, et al: Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
16. Fowler T: Medical Reports on the Effects of Arsenic in. London Med J 1786, pp 192-205.
17. PE B: Psoriasis. A brief historical review. Arch Derm Syph 1936; 33: 327-334.
18. Bechet P: History of the use of arsenic in dermatology. Arch Dermatol 1931; 23: 110-117.
19. Gruber F, Kastelan M, Brajac I: Psoriasis treatment-yesterday, today, and tomorrow. Acta Dermatovenerol Croat 2004; 12: 30-34.
20. Brault J: Deux cas de psoriasis traite par les injections mercurielles. Bull Soc Franc Dermatol 1895: 332.
21. Wolf R, Feuerman FJ: Failure of osmotic diuresis as therapy for psoriasis. Arch Dermatol 1983; 119: 95.
22. Menter A, Stoff B: Psoriasis. London, Manson Publishing Ltd., 2010.
23. Alderson HE: Heliotherapy for psoriasis. Arch Dermatol 1923; 8: 79-80.
24. Moscaliuc ML, Heller MM, Lee ES, Koo J: Goeckerman therapy: a very effective, yet often forgotten treatment for severe generalized psoriasis. J Dermatolog Treat 2013; 24: 34-37.
25. Tronnier H, Schule D: In Book of Abstracts, Symposia and Contributed Papers, 6th International Congress of Photobiology. Bochum, August 21-25, 1972.
26. Edmundson WF, Guy WB: Treatment of psoriasis with folic acid antagonists. AMA Arch Derm 1958; 78: 200-203.
27. Mueller W, Herrmann H: Ciclosporin A for psoriasis. N Engl J Med 1979; 301: 555.
28. Orfanos CE, Runne U: Systemic use of a new retinoid with and without local dithranol treatment in generalized psoriasis. Br J Dermatol 1976; 95: 101-103.
29. Smith EL, Walworth NC, Holick MF: Effect of 1 alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serumfree conditions. J Invest Dermatol 1986; 86: 709-714.
30. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG: Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the national psoriasis foundation surveys, 2003-2011. JAMA Dermatol 2013; 149: 1180-1185.
31. Manalo IF, Gilbert KE, Wu JJ: Time to raise the bar to psoriasis area severity index 90 and 100. J Drugs Dermatol 2015; 14: 1086-1088.
32. Gall JS, Kalb RE: Infliximab for the treatment of plaque psoriasis. Biologics 2008; 2: 115-124.
33. Nast A, Sporbeck B, Rosumeck S, et al: Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Invest Dermatol 2013; 133: 1963-1970.
34. Reich K, Nestle FO, Papp K, et al: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
35. Barker J, Hoffmann M, Wozel G, et al: Efficacy and safety of infliximab vs. methotrexate in patients with moderateto-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165: 1109-1117.
36. Saurat JH, Stingl G, Dubertret L, et al: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
37. Leonardi C, Langley RG, Papp K, et al: Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011; 147: 429-436.
38. Bissonnette R, Bolduc C, Poulin Y, Guenther L, Lynde CW, Maari C: Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol 2010; 63: 228-234.
39. Nguyen TU, Koo J: Etanercept in the treatment of plaque psoriasis. Clin Cosmet Investig Dermatol 2009; 2: 77-84.
40. Leonardi CL, Powers JL, Matheson RT, et al: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
41. Tyring S, Gottlieb A, Papp K, et al: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: doubleblind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
42. Benson JM, Peritt D, Scallon BJ, et al: Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immunemediated disorders. MAbs 2011; 3: 535-545.
43. Papp KA, Langley RG, Lebwohl M, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684.
44. Leonardi CL, Kimball AB, Papp KA, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
45. Kimball AB, Gordon KB, Fakharzadeh S, et al: Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012; 166: 861-872.
46. Griffiths CE, Strober BE, van de Kerkhof P, et al: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-128.
47. Langley RG, Elewski BE, Lebwohl M, et al: Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014; 371: 326-338.
48. Blauvelt A, Reich K, Tsai TF, et al: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol 2017; 76: 60-69.e9.
49. Griffiths CE, Reich K, Lebwohl M, et al: Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386: 541-551.
50. Gordon KB, Blauvelt A, Papp KA, et al: Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375: 345-356.
51. Blauvelt A, Lebwohl MG, Bissonnette R: IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol 2015; 135: 1946-1953.
52. Augustin M, Spehr C, Radtke MA, et al: German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges 2014; 12: 48-57.
53. Papp KA, Strober B, Augustin M, et al: PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 2012; 11: 1210-1217.
54. US National Institute of Health: A Multicenter, Open Registry of Patients with Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics. Bethesda, National Library of Medicine (US), 2007 (cited January 23, 2017).
55. Iskandar IY, Ashcroft DM, Warren RB, et al: Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol 2017; 176: 1297-1307.
56. Reich K, Mrowietz U, Radtke MA, et al: Drug safety of systemic treatments for psoriasis: results from the German Psoriasis Registry PsoBest. Arch Dermatol Res 2015; 307: 875-883.
57. Shalom G, Zisman D, Bitterman H, et al: Systemic therapy for psoriasis and the risk of Herpes Zoster: a 500,000 personyear study. JAMA Dermatol 2015; 151: 533-538.
58. Wendling D, Auge B, Bettinger D, et al: Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64: 788-789.
59. Singh JA, Saag KG, Furst D: Reply: to PMID 22473917. Arthritis Care Res (Hoboken) 2013; 65: 832-833.
60. Gottlieb AB, Kalb RE, Langley RG, et al: Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol 2014; 13: 1441-1448.
61. Strangfeld A, Eveslage M, Schneider M, et al: Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914-1920.
62. Grijalva CG, Chen L, Delzell E, et al: Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-2339.
63. Gordon KB, Langley RG, Leonardi C, et al: Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
64. Tyring S, Gordon KB, Poulin Y, et al: Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726.
65. van Oosten BW, Barkhof F, Truyen L, et al: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal antitumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-1534.
66. Simsek I, Erdem H, Pay S, Sobaci G, Dinc A: Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2007; 66: 1255-1258.
67. Winthrop KL, Chen L, Fraunfelder FW, et al: Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) study. Am J Ophthalmol 2013; 155: 183-189.e181.
68. Gabriel SE: Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis? Arthritis Rheum 2008; 58: 637-640.
69. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-811.
70. Schiff MH, Burmester GR, Kent JD, et al: Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889-894.
71. Solomon DH, Rassen JA, Kuriya B, et al: Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis 2013; 72: 1813-1818.
72. Safety alerts for drugs, biologics, medical devices, and dietary supplements. 2004. http://www.fda.gov/downloads/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm166923.pdf.
73. Hastings R, Ding T, Butt S, et al: Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2010; 62: 764-769.
74. Lee HH, Song IH, Friedrich M, et al: Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-491.
75. Asarch A, Gottlieb AB, Lee J, et al: Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61: 104-111.
76. Bene J, Moulis G, Auffret M, et al: Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. Rheumatology (Oxford) 2014; 53: 1465-1469.
77. Hernandez MV, Sanmarti R, Canete JD, et al: Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken) 2013; 65: 2024-2031.
78. Collamer AN, Battafarano DF: Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233-240.
79. Harrison MJ, Dixon WG, Watson KD, et al: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209-215.
80. Joyau C, Veyrac G, Dixneuf V, Jolliet P: Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 2012; 30: 700-706.
81. Hsu L, Snodgrass BT, Armstrong AW: Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol 2014; 170: 261-273.
82. Bito T, Nishikawa R, Hatakeyama M, et al: Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Br J Dermatol 2014; 170: 922-929.
83. FDA Approves Inflectra, a Biosimilar to Remicade. Food and Drug Administration, https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm494227.htm.
84. FDA Approves Amjevita, a Biosimilar to Humira. Food and Drug Administration, https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm522243.htm.
85. Lebwohl M, Leonardi C, Griffiths CE, et al: Long-term safety experience of ustekinumab in patients with moderateto-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials. J Am Acad Dermatol 2012; 66: 731-741.
86. Reich K, Papp KA, Griffiths CE, et al: An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012; 11: 300-312.
87. Reich K, Langley RG, Lebwohl M, et al: Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164: 862-872.
88. Papp KA, Griffiths CE, Gordon K, et al: Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844-854.
89. Jung J, Levin EC, Jarrett R, Lu D, Mann C: Lymphomatoid drug reaction to ustekinumab. Arch Dermatol 2011; 147: 992-993.
90. Stamell EF, Kutner A, Viola K, Cohen SR: Ustekinumab associated with flares of psoriatic arthritis. JAMA Dermatol 2013; 149: 1410-1413.
91. Kimball AB, Papp KA, Wasfi Y, et al: Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27: 1535-1545.
92. Leonardi C, Matheson R, Zachariae C, et al: Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-1199.
93. Saeki H, Nakagawa H, Ishii T, et al: Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2015; 29: 1148-1155.
94. Gordon KB, Leonardi CL, Lebwohl M, et al: A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 2014; 71: 1176-1182.
95. van de Kerkhof PC, Griffiths CE, Reich K, et al: Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 2016; 75: 83-98.e84.
96. Taleb S, Tedgui A, Mallat Z: IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol 2015; 35: 258-264.
97. Hueber W, Sands BE, Lewitzky S, et al: Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61: 1693-1700.
98. Paul C, Lacour JP, Tedremets L, et al: Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 2015; 29: 1082-1090.
99. Blauvelt A, Prinz JC, Gottlieb AB, et al: Secukinumab administration by prefilled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015; 172: 484-493.
100. Reich K, Blauvelt A, Armstrong A, et al: Secukinumab, a fully human antiinterleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2017; 176: 752-758.
101. Administration FaD: Drugs @ FDA website. http://www.fda.gov/Drugs/default.htm (accessed September 22, 2016).
102. Skomsvoll JF, Wallenius M, Koksvik HS, et al: Drug insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol 2007; 3: 156-164.
103. Khan N, Asim H, Lichtenstein GR: Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf 2014; 13: 1699-1708.
104. Clowse ME: The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int J Womens Health 2010; 2: 199-209.
105. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG: A 50% reduction in the psoriasis area and severity index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50: 859-866.
106. Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS: Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2017; 31: 213-220.
107. Kalb RE, Fiorentino DF, Lebwohl MG, et al: Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol 2015; 151: 961-969.
108. Blauvelt A, Lebwohl MG, Bissonnette R: IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol 2015; 135: 1946-1953.